酪胺酸激酶抑制劑市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、地區和競爭格局分類，2020-2030年預測

全球酪胺酸激酶抑制劑市場規模預計將從2024年的520.7億美元成長至2030年的830.9億美元，複合年成長率（CAGR）為8.10%。酪胺酸激酶抑制劑（TKIs）是一類旨在選擇性阻斷酪胺酸激酶活性的藥物。酪胺酸激酶是細胞訊號傳導、生長和分裂的關鍵酶，其作用機轉是抑制腫瘤增生。在全球範圍內，癌症發生率的不斷攀升是推動此類標靶療法市場成長的主要因素，這迫切需要先進且有效的治療方法。

主要市場促進因素

全球癌症發生率的不斷攀升是酪胺酸激酶抑制劑市場的主要驅動力。全球新增癌症病例的龐大數量，從根本上推動了對創新有效治療策略的需求。

主要市場挑戰

全球酪胺酸激酶抑制劑市場成長面臨的一大挑戰是這些先進療法的高昂成本。高昂的治療費用直接限制了病患的就醫途徑，尤其是在醫療系統預算緊張、公共報銷政策嚴格的地區。

主要市場趨勢

酪胺酸激酶抑制劑（TKI）聯合療法的日益普及標誌著治療模式的重大轉變，它不僅提高了療效，也有助於應對癌症中複雜的抗藥性機制。這一趨勢是將酪胺酸激酶抑制劑與其他藥物（例如化療或免疫療法）合併使用，以期獲得較佳的患者療效。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球酪胺酸激酶抑制劑市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（BCR-ABL酪胺酸激酶抑制劑、表皮生長因子受體（EGFR）酪胺酸激酶抑制劑、血管內皮生長因子受體（VEGFR）酪胺酸激酶抑制劑、其他）
  • 依申請類別（慢性骨髓性白血病(CML)、肺癌、乳癌、腎細胞癌、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美酪胺酸激酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲酪胺酸激酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區酪胺酸激酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲酪胺酸激酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美酪胺酸激酶抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球酪胺酸激酶抑制劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International
• Bristol-Myers Squibb Company
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company

第16章：策略建議

第17章調查會社について,免責事項

The Global Tyrosine Kinase Inhibitors Market will grow from USD 52.07 Billion in 2024 to USD 83.09 Billion by 2030 at a 8.10% CAGR. Tyrosine Kinase Inhibitors, or TKIs, are a class of pharmaceutical drugs designed to selectively block the action of tyrosine kinases, enzymes crucial for cell signaling, growth, and division, thereby inhibiting tumor proliferation. The global market for these targeted therapies is primarily driven by the escalating prevalence of cancer worldwide, which necessitates advanced and effective treatment modalities.

Key Market Drivers

The escalating global cancer incidence represents a primary impetus for the Tyrosine Kinase Inhibitors market. The sheer volume of new cancer diagnoses worldwide inherently drives the demand for innovative and effective therapeutic strategies. As the global population ages and lifestyles evolve, the burden of cancer continues to grow, necessitating targeted treatments that offer improved efficacy and patient outcomes.

Key Market Challenges

A significant challenge impeding the growth of the Global Tyrosine Kinase Inhibitors Market is the substantial cost associated with these advanced therapies. High treatment expenses directly restrict patient access, particularly in regions where healthcare systems operate under tight budgetary constraints and public reimbursement policies are stringent. This financial barrier limits the number of patients who can initiate and sustain TKI treatments, irrespective of medical need. Consequently, reduced patient uptake translates into lower sales volumes and slower market penetration for manufacturers of these inhibitors.

Key Market Trends

The increasing adoption of TKI combination therapies represents a pivotal shift in treatment paradigms, enhancing therapeutic efficacy and addressing complex resistance mechanisms in cancer. This trend involves combining tyrosine kinase inhibitors with other agents, such as chemotherapy or immunotherapies, to achieve superior patient outcomes.

Key Market Players

• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International
• Bristol-Myers Squibb Company
• Eisai Co. Ltd
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company

Report Scope:

In this report, the Global Tyrosine Kinase Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tyrosine Kinase Inhibitors Market, By Type:

• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
• Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
• Other

Tyrosine Kinase Inhibitors Market, By Application:

• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Other

Tyrosine Kinase Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tyrosine Kinase Inhibitors Market.

Available Customizations:

Global Tyrosine Kinase Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tyrosine Kinase Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other)
  • 5.2.2. By Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Tyrosine Kinase Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Tyrosine Kinase Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Tyrosine Kinase Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Tyrosine Kinase Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Tyrosine Kinase Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Tyrosine Kinase Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Tyrosine Kinase Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Tyrosine Kinase Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Tyrosine Kinase Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Tyrosine Kinase Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tyrosine Kinase Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bayer AG
• 15.3. Boehringer Ingelheim International
• 15.4. Bristol-Myers Squibb Company
• 15.5. Eisai Co. Ltd
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Johnson and Johnson
• 15.8. Novartis AG
• 15.9. Pfizer Inc.
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer